Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events

Elevated homocysteine levels are associated with increased coronary risk, and it has been suggested that homocysteine screening may provide a method to identify high-risk patients for aggressive primary prevention. Homocysteine was measured at baseline and after 1 year among 5569 participants in the...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2002-04, Vol.105 (15), p.1776-1779
Main Authors: RIDKER, Paul M, SHIH, Jessie, COOK, Thomas J, CLEARFIELD, Michael, DOWNS, John R, PRADHAN, Aruna D, WEIS, Stephan E, GOTTO, Antonio M
Format: Article
Language:English
Subjects:
Acute Disease
Aged
Anticholesteremic Agents - therapeutic use
Biological and medical sciences
C-Reactive Protein - analysis
Cholesterol, LDL - blood
Coronary Artery Disease - prevention & control
Coronary Disease - diagnosis
Coronary Disease - prevention & control
Double-Blind Method
Female
Follow-Up Studies
General and cellular metabolism. Vitamins
Homocysteine - blood
Humans
Lovastatin - therapeutic use
Male
Medical sciences
Middle Aged
Myocardial Infarction - diagnosis
Pharmacology. Drug treatments
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Elevated homocysteine levels are associated with increased coronary risk, and it has been suggested that homocysteine screening may provide a method to identify high-risk patients for aggressive primary prevention. Homocysteine was measured at baseline and after 1 year among 5569 participants in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), a randomized trial of lovastatin in the primary prevention of acute coronary events. The effects of homocysteine, LDL cholesterol, and lovastatin on risk were assessed over 5.2 years of trial follow-up. Median baseline homocysteine levels were significantly higher among study participants who subsequently had acute coronary events compared with those who did not (12.1 versus 10.9 micro;mol/L, P
ISSN:0009-7322
1524-4539
DOI:10.1161/01.CIR.0000014447.06099.FB